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Metformin is the first-line drug in type 2 diabetes mellitus because compared with other type 2 diabetes mellitus 
treatments, in both clinical trials and in observational studies, 
metformin monotherapy is associated with fewer adverse car-
diovascular events,1,2 and in some studies, a reduced risk of 
cancer.3 The reasons for this relative benefit are unclear, and 
Clinial Track
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.116.308445
Rationale: The diabetes mellitus drug metformin is under investigation in cardiovascular disease, but the molecular 
mechanisms underlying possible benefits are poorly understood.
Objective: Here, we have studied anti-inflammatory effects of the drug and their relationship to antihyperglycemic 
properties.
Methods and Results: In primary hepatocytes from healthy animals, metformin and the IKKβ (inhibitor of kappa 
B kinase) inhibitor BI605906 both inhibited tumor necrosis factor-α–dependent IκB degradation and expression 
of proinflammatory mediators interleukin-6, interleukin-1β, and CXCL1/2 (C-X-C motif ligand 1/2). Metformin 
suppressed IKKα/β activation, an effect that could be separated from some metabolic actions, in that BI605906 
did not mimic effects of metformin on lipogenic gene expression, glucose production, and AMP-activated protein 
kinase activation. Equally AMP-activated protein kinase was not required either for mitochondrial suppression 
of IκB degradation. Consistent with discrete anti-inflammatory actions, in macrophages, metformin specifically 
blunted secretion of proinflammatory cytokines, without inhibiting M1/M2 differentiation or activation. In a large 
treatment naive diabetes mellitus population cohort, we observed differences in the systemic inflammation marker, 
neutrophil to lymphocyte ratio, after incident treatment with either metformin or sulfonylurea monotherapy. 
Compared with sulfonylurea exposure, metformin reduced the mean log-transformed neutrophil to lymphocyte 
ratio after 8 to 16 months by 0.09 U (95% confidence interval, 0.02–0.17; P=0.013) and increased the likelihood 
that neutrophil to lymphocyte ratio would be lower than baseline after 8 to 16 months (odds ratio, 1.83; 95% 
confidence interval, 1.22–2.75; P=0.00364). Following up these findings in a double-blind placebo controlled trial 
in nondiabetic heart failure (trial registration: NCT00473876), metformin suppressed plasma cytokines including 
the aging-associated cytokine CCL11 (C-C motif chemokine ligand 11).
Conclusion: We conclude that anti-inflammatory properties of metformin are exerted irrespective of diabetes 
mellitus status. This may accelerate investigation of drug utility in nondiabetic cardiovascular disease groups.
Clinical Trial Registration: Name of the trial registry: TAYSIDE trial (Metformin in Insulin Resistant Left Ventricular 
[LV] Dysfunction). URL: https://www.clinicaltrials.gov. Unique identifier: NCT00473876.  
(Circ Res. 2016;119:652-665. DOI: 10.1161/CIRCRESAHA.116.308445.)
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metformin’s molecular action is a vigorous area of current re-
search.4–7 Metformin’s chemical properties include a strongly 
hydrophilic character, metal-binding properties, and a pK
a
 within 
the physiological pH range.6–8 The key clinical hallmark of met-
formin’s antihyperglycemic action is suppression of hepatocyte 
gluconeogenesis.4,5,9 The most likely cellular effect underlying 
this response is inhibition of mitochondrial enzymes, including 
complex I in the electron transport chain.10,11 More recently, mi-
tochondrial glycerophosphate dehydrogenase has been suggested 
as an alternative target.12 Mitochondrial inhibition activates AMP-
activated protein kinase (AMPK),13 and recent work suggests that 
duodenal AMPK contributes toward effects of the drug on hepatic 
glucose production.14 Other studies indicate that metformin also 
suppresses glucose production by AMPK-independent mecha-
nisms,12,15,16 but more broadly, AMPK may still contribute to 
metformin-dependent regulation of other aspects of metabolic 
control, such as lipogenic gene expression.4
The mechanism(s) underlying metformin’s advantage in 
incidence of cardiovascular disease (CVD) are unlikely to de-
pend on effects of the drug on hyperglycemia, which is con-
trolled equally well by metformin and insulin secretagogues.2 
In addition, in animals, metformin suppresses infarct size and 
adverse remodeling in diabetic and nondiabetic rodents17–21 
and retards heart failure progression in nondiabetic dogs.22 
A better understanding of such glucose-independent proper-
ties might foster a more rational, less empirical exploitation 
of metformin in nondiabetic CVD. Inflammation, including 
nuclear factor-κB (NF-κB) signaling, is increasingly recog-
nized as a significant contributing factor to diabetes mellitus 
(DM) and CVD,23,24 and several previous studies have found 
that metformin inhibits NF-κB signaling, including in vascu-
lar tissue25 and recently in hepatocytes.26 In the current study, 
we have used multiple approaches, including human studies, 
to define anti-inflammatory actions of metformin that may be 
separated from its antihyperglycemic action.
Methods
Animal and Cell Studies
Metformin and rapamycin came from calbiochem, 5-aminoimid-
azole-4-carboxamide riboside (AICAR) and A769662 (Tocris), 
tumor necrosis factor-α (TNF-α) (e-bioscience), recombinant 
CINC1/chemokine (C-X-C motif) ligand (CXCL) 1, C-C motif 
chemokine ligand (CCL)-11, interleukin (IL)-2, IL-4, stromal cell–
derived factor and CCL22 (R&D systems), mouse IL-6 (Sigma), 
and recombinant mouse IL-1β (Life Technologies). The phospho–
acetyl-CoA carboxylase Ser79 antibody was a generous gift from 
the DSTT (University of Dundee). The total acetyl-CoA carboxyl-
ase (Cat. number 3662), total AMPKα (2603), phospho-AMPKα 
Thr172 (2535), total S6 (2217), phospho-S6 Ser240/244 (2215), 
total p70 S6 kinase (2708), phospho-p70 S6 kinase Thr389 (9205), 
phospho-Raptor Ser 792 (2083), phospho inhibitor of kappa B ki-
nase (IKK) α/β Ser176/177 (2078), IKKα/β Ser176/180 (2697), 
total IκB, pNF-κB, total IKKα, and total IKKβ (NF-κB sampler 
kit 9936) antibodies were from CST. Antisheep horseradish per-
oxidase (31480) and antirabbit horseradish peroxidase (31460) both 
came from Thermo and antimouse horseradish peroxidase was from 
Calbiochem (JA1200). BI605906 was generously gifted by Prof Sir 
Philip Cohen (Dundee).
Animal Care
C57BL/6 female mice (Charles River; 8–41 weeks) were maintained 
under a 12 hours:12 hours light:dark cycle (holding room lights on at 
06:00 and off at 18:00) at 22±1°C and 50% humidity. Mice had ad 
libitum access to standard chow diet (7.5% fat, 75% carbohydrate, 
and 17.5% protein by energy [RM1 diet; Special Diet Services]) and 
water. All animal care protocols and procedures were performed in 
accordance with current regulations.
Cell Culture and Lysis for Immunoblotting
All cells were grown in an incubator at 37°C and 5% CO2. Primary 
mouse hepatocytes were extracted and maintained essentially as de-
scribed previously.6,15
Bone marrow–derived macrophages (BMDMs) were grown from 
mouse bone marrow in RPMI 1640 medium supplemented with 10% 
fetal bovine serum (Life Technologies) and 10-ng/mL macrophage 
colony-stimulating factor (R&D systems). Cells were given fresh 
medium and growth factor on day 3 of culture. On day 6, BMDM 
cultures were supplemented with 100-ng/mL interferon γ (for M1 dif-
ferentiation; R&D systems), 20-ng/mL IL-4 (for M2 differentiation; 
R&D systems), or 100-ng/mL lipopolysaccharide (for activation; 
premium grade from Sigma, expected to activate toll-like receptor 
[TLR]-2 and TLR4) in the presence or absence of drug treatments for 
the final 24 hours.
Before SDS-PAGE, cells were lysed by scraping into buffer A 
(50 mmol/L Tris acetate pH 7.5, 1% (wt/vol) Triton X100, 1 mmol/L 
EDTA, 1 mmol/L EGTA, 0.27 mol/L sucrose, 50 mmol/L NaF, 1 
mmol/L sodium orthovanadate, 10 mmol/L β-glycerophosphate, 5 
mmol/L sodium pyrophosphate, 1 mmol/L benzamidine, 0.2 mmol/L 
phenylmethylsulfonyl fluoride, and 0.1% (v/v) β-mercaptoethanol) 
and then prepared for SDS-PAGE as described in the previous work.6 
Immunoblot densitometry for each antibody was performed with 
Image Studio Lite version 5.2 (LI-COR). Each blot is representative 
of experiments preformed at least 3×.
Glucose Assay
Treatment of cells for hepatocyte glucose production was performed 
essentially as described previously, using primary mouse hepatocytes 
plated in 12-well plates (1.25×105 cells per well).6,15,27 Glucose pro-
duction was determined after a 12-hour incubation period in glucose-
free DMEM (11966; Life Technologies) supplemented with 1% pen/
strep, lactate (Sigma)/pyruvate (Life Technologies; 10:1 mmol/L), 
and 100 nmol/L dexamethasone (dex; Merck) with or without drugs/
cytokines under investigation. At the end of the incubation period of 
12 hours, 500 μl of medium was collected and glucose concentra-
tion determined by GAGO assay (glucose [glucose oxidase]; Sigma) 
by a modified protocol scaled down to a 96-well plate format. Each 
column consists of data from at least 12 wells of cells, 6 each from 
2 mice.
Real-Time-Polymerase Chain Reaction
Total RNA from primary mouse hepatocytes was extracted using 
QIAshredder (Qiagen) and Rneasy MINI KIT (Qiagen). cDNA was 
Nonstandard Abbreviations and Acronyms
AICAR 5-aminoimidazole-4-carboxamide riboside
AMPK AMP-activated protein kinase
BMDM bone marrow–derived macrophages
BMI body mass index
CCL C-C motif chemokine ligand
CVD cardiovascular disease
CXCL chemokine (C-X-C motif) ligand
DM diabetes mellitus
FIRI Fasting Insulin Resistance Index
IR insulin resistant
NFκB nuclear factor κ-light-chain-enhancer of activated B cells
NLR neutrophil to lymphocyte ratio
TLR toll-like receptor
TNFα tumor necrosis factor-α
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synthesized using RQ1 Rnase-Free Dnase kit (Promega) and ImProm-
II Reverse Transcription System (Promega). Nucleospin RNA II Total 
RNA isolation kit (Macherey-Nagel) was used to isolate RNA from 
macrophages. cDNA was synthesized using High Capacity cDNA 
Reverse Transcription Kit (4368814, Thermo Fisher Scientific). Real-
time polymerase chain reaction was performed using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems) using TaqMan 
2× Universal PCR Master Mix (Applied Biosystems) and primer/
probes mixes as stated (Applied Biosystems). Primer sets used were 
as follows: IL-6 Mm00446190_m1, CXCL1 Mm04207460_m1, 18S 
Hs03003631_g1, IL-1β Mm00434228_m1, CXCL2 Mm00436450_
m1, peroxisome proliferator–activated receptor-γ m01184322_m1, 
fatty acid synthase Mm00662319_m1, CCL22 Mm00436439_ml, 
CXCL12 Mm00445553_ml, TATA-binding protein Mm01277042_
m1, and sterol regulatory element-binding protein 1c Mm00550338_
m1. Cycling conditions were as follows: 50°C for 2 minutes, 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 15 s and 60°C 
for 1 minute. Expression is expressed relative to 18s mRNA for 
hepatocytes and TATA-binding protein for macrophages (Applied 
Biosystems) using the 2-ΔΔCt method. Each column is composed of 
data from at least 3 separate experiments.
BMDM Analysis
BMDMs were harvested from culture plates using 4 mmol/L EDTA 
in PBS for 10 minutes at 37°C. Cells were washed in flow cytom-
etry buffer (PBS with 2% fetal bovine serum and 1 mmol/L EDTA) 
and stained using the following antibodies (all BD Bioscience unless 
stated): F4/80 (BM8; e-bioscience), CD11c (HL3), CD206 (C068C2; 
Biolegend), CD69 (H1.2F3), and CD40 (3/23). Fc block (4.4G2) was 
included in all stains. Data were acquired on a LSR II flow cytometer 
(Becton Dickinson) and analyzed using FlowJo software (TreeStar). 
BMDM culture supernatants were collected after 24-hour treatment 
with the differentiation or activation conditions. Levels of cytokines 
were quantified by standard sandwich ELISA using paired antibody 
kits (e-bioscience).
Validation in Clinical Patients
We validated the animal study findings in clinical patients utilizing 
2 approaches: a retrospective population cohort study and a random-
ized placebo-controlled study of metformin. All patients provided 
written informed consent to participate in these clinical studies that 
were approved the local ethics committee.
Population Cohort Study: Metformin Exposure in 
DM Patients and Neutrophil to Lymphocyte Ratio.
In the population cohort study, we investigated whether the anti-in-
flammatory signature of metformin could be detected in humans with 
DM, using the GoDARTS (Genetics of Diabetes Audit and Research 
in Tayside Scotland) DM register.28 We compared the effect of metfor-
min and sulfonylureas on the neutrophil to lymphocyte ratio (NLR), 
a marker of inflammation derived from a combination of hematologi-
cal components of the systemic inflammatory response29,30 that has 
recently been found to be a predictor of all-cause mortality and car-
diac events.31 We analyzed data from type 2 diabetes mellitus patients 
recruited in Tayside, Scotland, UK, between October 1, 1997, and 
March 1, 2010. Of the 9205 subjects with DM within the GoDARTS 
study, we chose 3575 treatment naive patients who were either inci-
dent metformin users or incident sulfonylurea users (but not both) 
and noninsulin users. Incident use meant at least 6 months before 
first observed metformin/sulfonylurea prescription date during which 
they were observable for drugs. Of these 670 patients (mean [SD]: 
age, 65 [11] years; 54% men) had derived NLR values both at base-
line (up to 120 days before first metformin/sulfonylurea prescription) 
and follow-up (8–16 months after baseline). NLR was calculated as 
the ratio of the neutrophil:lymphocyte count, both obtained from the 
same blood sample. A total of 498 (74%) patients were treated with 
metformin and 172 (26%) with sulfonylurea. Multivariate linear and 
logistic regression models were run on the 8- to 16-month follow-up 
NLR against the treatment group, controlling for covariates including 
age, sex, and baseline NLR value.
Randomized Placebo-Controlled Study: Metformin 
Exposure and Cytokine Levels in Nondiabetic Heart 
Failure Patients
The anti-inflammatory effects of metformin were investigated in 
a randomly selected subset of patients who had participated in a 
double-blind, placebo-controlled study (www.clinicaltrials.gov: 
NCT00473876) that had evaluated the impact of metformin on in-
sulin resistant (IR) and exercise capacity in nondiabetic patients 
with congestive heart failure.32 Every patient had provided written 
informed consent before participation in this study, which was ap-
proved by the East of Scotland Research Ethics Service. The subset of 
patients selected for this study involved 33 nondiabetic IR congestive 
heart failure patients (mean age, 63±7.0 years; men, 85%; New York 
Heart Association class I/II/III/IV, 04/28/01/0) who were randomized 
to receive either 4 months of metformin (n=20; 2 g/d) or matching 
placebo (n=13). IR was defined by a fasting insulin resistance index 
(FIRI) of ≥2.7. The effect of metformin on plasma inflammatory cy-
tokines was examined by investigating changes from baseline to final 
visit after 4 months in the study.
Cytokine Assay
Human plasma was analyzed using the Bio-Plex Pro Human 
Chemokine 40-Plex Panel (171-AK99MR2, Bio-Rad). The assay 
was performed following the manufacturer’s instructions using the 
Bio-Plex 200 system (Bio-Rad). Freeze–thaw cycling of samples was 
avoided to prevent cytokine degradation, and they were diluted 1:4 
(12.5 μL of plasma) for the assay.
Statistical Analyses
Results in bar graphs are expressed as mean±SEM. Comparisons be-
tween groups were made by 1-way ANOVA with Dunnett or Tukey 
post hoc test using Prism. Differences were considered statistically 
significant if P<0.05: ***P<0.001, **P<0.01, and *P<0.05 unless 
otherwise stated. For studies on the plasma, statistical analyses of 
data were performed using SPSS 14.1. ANOVA and Pearson correla-
tion coefficients were calculated.
Results
Metformin Inhibits TNF-α–Dependent NF-κB 
Inflammatory Signaling, Comparably With the 
Specific IKKβ Inhibitor BI605906
In primary mouse hepatocytes, the main target of metformin’s 
antihyperglycemic effects, we compared metformin with the 
specific IKKβ inhibitor BI605906.33 Metformin treatment for 
3 hours suppressed TNFα-induced degradation of the NF-κB 
negative regulator IκB, while modulating AMPK and mamma-
lian target of rapamycin signaling in a dose-dependent man-
ner (Figure 1A through 1C; all densitometry appears in the 
Online Data Supplement). The magnitude of the effect on IκB 
was comparable with BI605906 (Figure 1A and 1D). Unlike 
metformin, BI605906 did not suppress signaling downstream 
of mammalian target of rapamycin nor did it activate AMPK 
(Figure 1E and 1F). We were unable to detect any effect of 
rapamycin on NF-κB signaling either (Figure 1D), suggesting 
that the effect of metformin on NF-κB and mammalian tar-
get of rapamycin occurs independently. Consistent with these 
signaling results, TNF-α–dependent expression of CINC-1/
CXCL1, CXCL2, IL-1β, and IL-6 was strongly inhibited by 
both metformin and BI605906 (Figure 1G through 1J).
AMPK-Independent Regulation of NF-κB in 
Primary Hepatocytes
To determine whether metformin directly regulated kinase 
activity that may mediate its effects on NF-κB signaling, a 
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Figure 1. Effect of metformin on nuclear factor-κB (NF-κB) signaling and gene expression. A–C, Primary hepatocytes were incubated 
in serum-free medium overnight and then stimulated for 3 h with or without 0.5 to 5 mmol/L metformin. For the last 15 min, cells were treated 
with or without 10 ng/mL tumor necrosis factor (TNF)-α. Cells were lysed and prepared for immunoblotting using antibodies as described 
in the Methods section of this article. In this figure and elsewhere, each blot is representative of experiments carried out at least 3×. D–F, 
Primary hepatocytes were incubated as in A–C, before stimulation for 3 h with or without 2 mmol/L metformin and TNF-α. In addition, cells 
were incubated with/without 10 μmol/L BI605906 or 100 nmol/L rapamycin as shown, before lysis and immunoblotting as described in the 
Methods section of this article. G–J, Primary hepatocytes were treated with or without 10 ng/mL TNF-α, 2 mmol/L metformin, or 10 μmol/L 
BI605906 for 8 h followed by cell lysis, RNA extraction, and preparation of cDNA for real-time-polymerase chain reaction using primer sets 
for individual genes shown as described in the Methods section of this article. ACC indicates acetyl-CoA carboxylase; AMPK, AMP-activated 
protein kinase; p-ACC, phospho–acetyl-CoA carboxylase; and pAMPK, phospho–AMP-activated protein kinase.
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cell-free kinase profiling assay was performed. Metformin 
did not directly inhibit the upstream NF-κB regulator IKKβ, 
and most other kinases exhibited little, if any, inhibition by 
metformin and none were inhibited >50% (data available on 
the profiling website http://www.kinase-screen.mrc.ac.uk/). 
These results suggest that metformin is unlikely to exert ef-
fects on NF-κB through direct IKKβ inhibition or inhibition of 
other kinases. The lack of effect of metformin on kinase activ-
ity led us to explore the possibility that IκB regulation might 
occur as a consequence of AMPK activation,13 which occurs 
after mitochondrial inhibition by the drug.10,11 In side-by-side 
experiments, we treated primary hepatocytes with AICAR 
(an AMP mimetic) and A769662, a direct AMPK activator. 
Compared with AICAR, which suppressed IκB degradation, 
there was little, if any, effect of A769662 on IκB degrada-
tion at the doses used (Figure 2A), but both agents induced 
phosphorylation of the AMPK substrate acetyl-CoA carbox-
ylase (Figure 2B). To investigate possible reason(s) for this 
difference, we investigated primary liver cells from AMPK 
catalytic subunit-deficient mice.15 In these cells, AICAR still 
suppressed IκB degradation (Figure 2C), suggesting that 
AICAR effect is AMPK independent. Consistent with this, 
the effect of metformin on IκB signaling was similar in both 
genotypes (Figure 2D).
Dissociation of Anti-Inflammatory Responses 
From Effects of Metformin on Hepatic Glucose 
Production and Lipogenic Gene Expression
Metformin’s main antihyperglycemic effect is to reduce he-
patic glucose production. To determine whether metformin-
regulated cytokines directly altered glucose production, we 
incubated hepatocytes with and without metformin, IL-6, 
IL-1β, CXCL1, and TNFα. CXCL1 significantly increased 
glucose production (Figure 3A). In all groups, metformin re-
duced glucose production to below control levels (basal) in the 
presence or absence of cytokine. Incubation of hepatocytes 
with BI605906 did not mimic the effect of metformin, nor was 
there any modulation of metformin’s suppression of glucose 
production (Figure 3B).
Next, we compared the effect of metformin and BI605906 
on lipogenesis, which is an another metabolic response 
known to be regulated by metformin. Proinflammatory cy-
tokines including TNF-α are known to induce lipogenesis.34 
This prompted us to study the effects of TNF-α on lipogenic 
genes sterol regulatory element-binding protein 1c, peroxi-
some proliferator–activated receptor-γ, and fatty acid syn-
thase, which are known to be regulated by metformin in 
hepatocytes.13,32,35 TNF-α significantly increased fatty acid 
synthase mRNA expression, with a trend toward increased 
expression of sterol regulatory element-binding protein 1c 
and peroxisome proliferator–activated receptor-γ (Figure 3C 
through 3E). Metformin reduced mRNA expression of all 
3 genes and prevented TNF-α–induced increases. In con-
trast to the inflammatory genes, coincubation of BI605906 
and TNF-α increased lipogenic gene expression (Figure 3C 
through 3E). BI605906 alone did not alter sterol regulatory 
element-binding protein 1c, fatty acid synthase, or peroxi-
some proliferator–activated receptor-γ; however, this com-
pound significantly augmented TNF-α–induced expression 
of each gene. This may be related to the existence of negative 
feedback loops in NF-κB signaling.33
Direct Anti-Inflammatory Effect of Metformin on 
Macrophage Cytokine Secretion
Our evidence that metformin inhibits inflammatory respons-
es in hepatocytes independently of some metabolic actions 
prompted us to study inflammatory responses in extrahepatic 
tissues. Macrophages may undergo classical proinflammatory 
M1 activation in response to cues including lipopolysaccha-
ride and interferon γ. However, in response to agents including 
IL-13 and IL-4, they may become M2 cells, which are gener-
ally thought of as having anti-inflammatory or tissue repair ac-
tions.36 We studied the effects of metformin and another drug 
biguanide (structurally this drug is the same as metformin ex-
cept that it lacks the 2 methyl groups present in metformin), 
which we have found previously acts similar to metformin on 
hepatocytes.6 We investigated 3 aspects: macrophage differ-
entiation, activation, and secretion of cytokines. We measured 
effects on bone marrow–derived macrophage (BMDM) differ-
entiation into M1 and M2 macrophages, using expression of 
CD11c as a marker of M1 differentiation and CD206 as a mea-
sure of M2 differentiation. In addition, we investigated mac-
rophage activation in response to lipopolysaccharide, which 
acts on the toll-like receptor TLR4, increasing expression of 
CD69 and CD40. There was no significant effect of the drugs 
on expression of any of these markers (Figure 4A and 4B). As 
in hepatocytes, metformin suppressed IL-1β gene expression 
in macrophages (Online Figure IIIA), but somewhat reminis-
cent of the effect of BI605906 on lipogenic genes, metformin 
increased expression of the other cytokines we had studied 
in hepatocytes (Online Figure IIIB–IIID). We did, however, 
observe further drug-induced reductions when we measured 
cytokine secretion, to investigate macrophage activity and dif-
ferentiation more directly. The 3 cytokines we studied were 
inflammatory cytokines IL-12p40, IL-6, and the anti-inflam-
matory cytokine IL-10 in these TLR-triggered cells. Both 
drugs reduced IL-12p40 and IL-6 secretion but were without 
effect on IL-10 secretion (Figure 4C through 4E).
Chronic Treatment of Hepatocytes With Low Doses 
of Metformin Triggers Anti-Inflammatory Signaling 
Responses Similar to Those Resulting From High-
Dose Acute Treatment
Plasma levels of metformin in the clinical setting are under-
stood to be in the low micromolar range.4,9 Consequently, 
metformin-treated individuals may have lower intracellular 
concentrations of metformin than in our cell experiments, but 
the duration of exposure will be much longer. Discrepancies in 
effective concentrations of metformin likely occur because of 
the length of exposure, as the drug must accumulate in active 
mitochondria over several hours.10,37 In hepatocytes, long-term 
(24 hours) effects of the drug on NF-κB signaling occurred at 
concentrations close to the physiological range and this was 
unaffected by genotype (Figure 5A through 5C).
To provide more insight into the site of metformin ac-
tion, we investigated signaling further upstream of IKK 
(Figure 5A). We found that TNF-α–induced phosphoryla-
tion of the upstream kinase site p176/17738 on IKKα/β was 
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suppressed by metformin. In supporting studies, we found that 
propanediimidamide, a close structural analogue of metfor-
min that we have found does not inhibit the mitochondria,6 
does not inhibit IκB degradation, nor does it suppress phos-
phorylation of IKKα/β (Figure 5A). Consistent with the notion 
that NF-κB signaling can respond to mitochondrial inhibition 
Figure 2. Effect of 5-aminoimidazole-4-carboxamide riboside (AICAR) and A769662 on nuclear factor-κB (NF-κB) signaling. A–D, 
Primary wild-type (WT) hepatocytes (A and B) and those taken from double-knockout (KO) AMPK animals or matched controls (WT) (C) were 
incubated in serum-free medium overnight, before stimulation for 3 h with or without doses of A769662 and AICAR as shown. For the last 15 
min, cells were treated with or without 10 ng/mL tumor necrosis factor (TNF)-α. D, Hepatocytes from KO or WT animals treated with and without 
doses of metformin for 3 h. For the last 15 min, cells were treated with 10 ng/mL TNF-α. Cells were then lysed, and immunoblots were prepared 
as described in the Methods section of this article and in Figure 1. ACC indicates acetyl-CoA carboxylase; AMPK, AMP-activated protein 
kinase; IKK, inhibitor of kappa B kinase; p-ACC, phospho–acetyl-CoA carboxylase; and pAMPK, phospho–AMP-activated protein kinase.
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independently of AMPK, we found that the complex I inhibi-
tor rotenone prevented TNF-α–dependent IκB degradation in 
both genotypes (Figure 5D).
Anti-Inflammatory Effects of Metformin in a DM 
Population Cohort
Next, we compared the effect of metformin and sulfonyl-
ureas on the NLR, a marker of inflammation that has recently 
been found to be a predictor of all-cause mortality and car-
diac events.31 To test the hypothesis that metformin reduces 
inflammation using the GoDARTS diabetic cohort, we chose 
individuals prescribed metformin alone (without sulfonylurea 
or insulin) or sulfonylurea alone (without metformin or insu-
lin), and for whom NLR measurements were available in the 
120 days before first metformin/sulfonylurea prescription (the 
baseline measure) and 12 months after the first prescription 
(within a 8–16-month window). There were 498 people in met-
formin group and 172 in sulfonylurea group. Baseline charac-
teristics of the 2 groups are shown in Table 1. Comparison 
Figure 3. Effects of cytokines on glucose production and lipogenic gene expression in primary hepatocytes. A and B, Primary 
hepatocytes were treated with/without metformin (2 mmol/L), interleukin (IL)-6 (5 ng/mL), IL-1β (10 ng/mL), chemokine (C-X-C motif) 
ligand (CXCL) 1 (100 ng/mL) and tumor necrosis factor (TNF)-α (10 ng/mL) for 12 h, and glucose production was measured by GAGO 
(glucose [glucose oxidase]) assay as described in the Methods section of this article. C–E, Primary hepatocytes were treated with or 
without 10 ng/mL tumor necrosis factor (TNF)-α, 2 mmol/L metformin, and 10 μmol/L BI605906 for 8 h followed by cell lysis, RNA 
extraction, and preparation of cDNA for real-time polymerase chain reaction using primer sets for individual genes shown as described 
in the Methods section of this article. FASN indicates fatty acid synthase; PPAR, peroxisome proliferator–activated receptor; and 
SREBP, sterol regulatory element-binding protein.
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of the 2 groups showed a significant effect of metformin 
exposure compared to sulfonylurea, with 12-month log-
transformed NLR 0.09 lower in the metformin group (95% 
confidence interval [CI], 0.02–0.17; P=0.01), controlling for 
baseline values. This is equivalent to a 9% (95% CI, 2–15) 
lower geometric mean NLR. In addition, a logistic regression 
of 12-month NLR being lower than the baseline NLR gave an 
odds ratio of 1.83 (95% CI, 1.22–2.75; P=0.0034) for the met-
formin group compared with the sulfonylurea group (Tables 2 
and 3). Body mass index (BMI) both nearest baseline and fol-
low-up (4% missing) was not a significant variable (P=0.7), 
so was excluded. Inclusion of baseline HbA1c (19% missing) 
in the models resulted in similar effects. To examine the effect 
of metformin on high values on NLR, the models were rerun 
including only subjects with baseline NLR above the respec-
tive group median values (Tables 4 and 5). These showed a 
stronger metformin effect in the linear model, equivalent to 
a 15% (95% CI, 5–23) lower geometric mean NLR and an 
unchanged metformin effect for the logistic model, odds ratio 
of 1.91 (1.02–3.59). These results are summarized in Table 6.
To control for the different characteristics of the met-
formin and sulfonylurea groups, further analyses following 
propensity-score matching were performed. Nearest-neighbor 
one-to-one matching on DM duration, BMI, age, and angio-
tensin-converting enzyme exposure at baseline resulted in a 
reduced matched cohort of 318 (47% of original). Refitting 
the linear model using this cohort showed a similar effect 
of metformin exposure compared with sulfonylurea, with 
12-month log-transformed NLR 0.10 lower in the metformin 
group (95% CI, 0.01–0.20; P=0.03). The logistic model for 
12-month NLR lower than the baseline NLR gave an odds 
ratio of 1.53 for the metformin group compared with the sul-
fonylurea group; however, this effect was not statistically sig-
nificant (95% CI, 0.93–2.52; P=0.096).
Effect of Metformin on Inflammation in 
Nondiabetic Heart Failure
Given evidence that the anti-inflammatory effects of met-
formin may be dissociated from some metabolic responses 
in cells and from glycemic responses in DM, we further in-
vestigated the anti-inflammatory effects of metformin in a 
placebo-controlled clinical trial of metformin in a group of 
nondiabetic IR heart failure patients.39 In this study, com-
pared with placebo, metformin significantly improved FIRI 
and resulted in a significant reduction in weight loss of 1.9 
kg and BMI. Metformin treatment also reduced the prespeci-
fied secondary end point of the slope of the ratio of minute 
ventilation:carbon dioxide production.39 We analyzed plasma 
from 33 patients who took part in this study and performed 
multivariate ANOVA on all 40 cytokines with treatment (with 
and without metformin, 20 allocated to metformin and 13 to 
Figure 4. Effect of metformin and its analogue biguanide on bone marrow–derived macrophages: phenotypic markers and 
cytokine secretion. A, Macrophages were treated with/without metformin (2 mmol/L) or biguanide (BIG 2 mmol/L) to determine the 
effect on the M1 and M2 phenotypes of macrophages, which was measured by flow cytometry for CD11c and CD206 expression. The 
colors denote the following: red, undifferentiated; blue, differentiated, untreated; orange, differentiated, metformin; green, differentiated, 
BIG. B, Macrophages were treated with/without metformin (2 mmol/L) or biguanide (BIG, 2 mmol/L) to determine the effect on activation 
in response to 100 ng/mL lipopolysaccharide (LPS), which was measured by studying CD69 and CD40 expression. Histograms are 
representative of n=4. The colors denote the following: red, unactivated; blue, activated, untreated; orange, activated, metformin; green, 
activated, BIG. C–E, Macrophages were treated with/without metformin (Met) or BIG (2 mmol/L) to determine the effect of these drugs on 
IL-6 (C), IL-12p40 (D), and IL-10 (E) production (n=4).
 at U
N
IV
 LIBRA
RY
 on A
ugust 23, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
660  Circulation Research  August 19, 2016
Figure 5. Effect of long-term metformin treatment on nuclear factor-κB (NF-κB) signaling responses in hepatocytes. A and 
B, Primary hepatocytes were treated as in Figure 1 with metformin or propanediimidamide (PDI) at the doses indicated except that the 
treatment time was 24 h. For the last 15 min, cells were treated with 10 ng/mL tumor necrosis factor (TNF)-α. In addition to antibodies 
used elsewhere, phosphorylation of inhibitor of kappa B kinase (IKK)α/β was investigated using the phosphospecific antibodies indicated. 
After cell lysis, SDS-PAGE and immunoblotting were performed as in Figure 1. C and D, Hepatocytes from wild-type (WT) and AMPK 
double-knockout (KO) livers treated as in A or with doses of rotenone for 45 min before cell lysis, SDS-PAGE and immunoblotting. E, 
Primary hepatocytes were treated in the presence or absence of the agents shown. Cells were treated with/without metformin (2 mmol/L), 
C-C motif chemokine ligand (CCL)-11 (5 ng/mL), interleukin (IL)-2, IL-4, stromal cell–derived factor (SDF), and CCL22 (10 ng/mL) for 12 h, 
and glucose production was measured by GAGO (glucose [glucose oxidase]) assay as described in the Methods section of this article. ACC 
indicates acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; p-ACC, phospho–acetyl-CoA carboxylase; and pAMPK, phospho–
AMP-activated protein kinase.
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placebo) as the main factor and change in BMI as a covariate. 
This covariate analysis identified 5 cytokines that were signifi-
cantly suppressed by metformin, after controlling for change 
in BMI (Table 7). Investigating these cytokines further, we 
performed Pearson correlations to identify cytokines signifi-
cantly affected by metformin that correlated with a change in 
BMI. Among the 5 cytokines, correlations were observed for 2 
of the 5 cytokines, CCL22 and CXCL12 (Table 8). Metformin 
improved insulin sensitivity as shown by significant reduction 
in FIRI (t=2.765, df=30.762; P<0.01) when an independent 
sample t test (equal variances not assumed) is performed; 
however, there was no significant correlation between change 
in FIRI and any change in the cytokines in the panel using a 
Pearson correlation. When a second correction for change in 
FIRI was applied, in addition to change in BMI, 4 of the 5 
original cytokines remained significantly different with treat-
ment (Table 7).
Most of the cytokines suppressed by metformin in plasma 
were not measurable in hepatocytes or macrophages and for 
those that could be measured, metformin did not inhibit their 
expression in these cell types (Online Figure IV). Similar 
to our earlier studies, these cytokines had little, if any, ef-
fect on inducing glucose production in hepatocytes and met-
formin could still suppress this parameter in their presence 
(Figure 5E). All details of cytokine changes, metabolic, hemo-
dynamic, and other parameters of these patients are described 
in Online Tables I and II.
Discussion
We have used pharmacological and genetic approaches to 
isolate anti-inflammatory effects of metformin from those 
on glucose in cells, plasma, patient records, and in a place-
bo-controlled study. Initiating the study in hepatocytes, we 
separated signaling effects of metformin on the metabolic 
regulator AMPK from effects on inflammatory signaling. 
Although the AMPK activator AICAR induced similar ef-
fects to metformin on IκB degradation, AMPK was not re-
quired for these effects. In long-term treatment, effects of 
metformin on NF-κB signaling occurred at concentrations 
toward the physiological range, and in further studies, we 
found that propanediimidamide, a close structural analogue 
of metformin that does not inhibit the mitochondria,6 does 
not inhibit IκB degradation, nor does it increase phosphory-
lation of IKKα/β as is observed with metformin. Consistent 
with the possibility that NF-κB signaling can respond to 
Table 1. Baseline Measurements of GoDARTS (Genetics of 
Diabetes Audit and Research in Tayside Scotland) Diabetes 
Cohort
Variable
Metformin 
(n=498)
Sulfonylurea  
(n=172) P Value
Age, y* 65 (57–72) 69 (61–76) 0.042
Sex (% of men) 55 51.2 0.432
Diabetes mellitus 
duration, y*
2.1 (0.2–5) 0.95 (0.1–4.2) 0.00193
Body mass index, 
kg/m2*
32 (29–35.98) 27.2 (24.4–31.05) 2.26E−14
HbA1c, %* 8.2 (7.6–9.1) 8.4 (7.5–9.6) 0.471
Neutrophil to 
lymphocyte ratio*
1.94 (1.5–2.62) 2.56 (1.868–3.89) 2.47E−06
Neutrophils (×109/L)* 4.2 (3.3–5.5) 4.8 (3.775–6.225) 0.00103
Lymphocyes 
(×109/L)*
2.1 (1.7–2.8) 1.8 (1.4–2.3) 1.19E−05
Platelets (×109/L)* 236 (199–280) 251.5 (198–305.5) 0.133
C- reactive protein, 
mg/L*
10 (5–16.75) 10 (4.1–20) 0.854
Creatinine, μmol/L 86 (75–98) 94.5 (78–120.8) 0.000172
Bilirubin, μmol/L* 9(7–13) 9 (7–11.75) 0.069
Albumin, g/L* 44(42–45) 41(38–43) 1.35E−10
Urea, mmol/L* 5.8 (4.8–6.8) 6.6 (5.075–9.325) 0.000644
Medications, n (%)
  Angiotension-
converting enzyme 
inhibitors
41 23.8 8.53E−05
  Angiotensin 
receptor blockers
11.8 7 0.0999
  β-blocker 32.1 28.5 0.428
  Digoxin 4.4 9.9 0.0143
  Anticoagulants 6 10.5 0.0758
  Calcium channel 
blocker
30.5 24.4 0.154
  Antiplatelets 37.3 31.4 0.19
*Median (inter-quartile range).
Table 2. Regression Coefficients of Linear Model (log-NLR)
Estimate SE 95% CI P Value
Sex, men 0.054775 0.031656 −0.00727 to 0.117 0.084038
Age, y −0.035556 0.012157 −0.0594 to −0.0117 0.003567
Age2, y 0.000281 0.000095 9.51e−05 to 
0.000467
0.003163
log(NLR) at 
baseline
0.498068 0.030933 0.437 to 0.559 <10–5
Group: 
metformin
−0.093859 0.037702 −0.168 to −0.0200 0.013037
CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.
Table 3. Regression Coefficients of Logistic Model 
(NLR_12<NLR_0)
Estimate SE 95% CI P Value
Sex, men −0.2280 0.1703 −0.562 to 0.106 0.1804
Age, y 0.1450 0.0669 0.0139 to 0.276 0.0302
Age2, y −0.0012 0.0005 −0.00218 to 
−0.000133
0.0267
log(NLR) at 
baseline
1.9456 0.2128 1.528 to 2.363 <10–5
Group: 
metformin
0.6054 0.2078 0.198 to 1.013 0.0036
CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.
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mitochondrial inhibition independently of AMPK, we 
found that metformin and rotenone each prevented TNF-α–
dependent IκB degradation in an AMPK-independent man-
ner. Considering information from these pharmacological 
and genetic experiments, our data indicate that metformin 
acts upstream of IKKα/β through an AMPK-independent 
mechanism dependent on mitochondrial inhibition. This 
mechanism is fully consistent with our other observations 
that metformin does not directly inhibit IKK in vitro. These 
studies do not exclude the possibility of AMPK-dependent 
mechanisms contributing to anti-inflammatory actions of 
metformin in other ways. Effects of metformin on anti-in-
flammatory signaling pathways were separable from other 
metabolic responses to the drug. Inhibition of NF-κB signal-
ing had little effect, for example, on glucose production or 
lipogenic gene expression, 2 key metabolic actions of met-
formin. Moreover, addition of cytokines suppressed by met-
formin in hepatocytes, plasma, or macrophages did not block 
the effect of the drug on glucose production. Taken together, 
these results define a dual action of metformin, with anti-in-
flammatory effects occurring alongside known antihypergly-
cemic and other metabolic effects. These 2 strands are both 
likely to be triggered by a mitochondrial target of the drug.
The evidence that metformin can suppress inflammatory 
signaling independently of some of its metabolic effects led 
us to investigate nonhepatic anti-inflammatory responses. 
Previous studies have suggested that inflammatory signal-
ing on macrophages influences insulin sensitivity in other 
tissues. Loss of the lipopolysaccharide receptor TLR4, for 
example, confers some protection from insulin resistance fol-
lowing a high-fat diet.40 In addition, M2 macrophages domi-
nate in adipose tissue in lean mice, whereas M1 macrophages 
accumulate in adipose tissue during obesity and are thought to 
contribute to systemic insulin resistance.41 At the level of gene 
expression, there were some differences between the effect of 
metformin in hepatocytes and macrophages although IL-1β 
was suppressed in both cell types. Studying cytokine secre-
tion from macrophages, we found that metformin acted highly 
selectively to reduce proinflammatory cytokine secretion from 
activated macrophages, without affecting anti-inflammatory 
cytokine secretion and markers of macrophage differentiation 
and activation. This targeted mechanism may allow selective 
ablation of the ability of M1 macrophages to induce systemic 
insulin resistance in obesity. Taken together with the results 
in hepatocytes, this work suggests that metformin’s anti-in-
flammatory actions are likely to be qualitatively different from 
conventional NSAIDs.
We wished to establish whether the effects of metformin 
could be detected in humans and we started with a DM co-
hort. Investigating the GoDARTS patient database, we found 
evidence of metformin reducing subclinical inflammation as 
measured by NLR in patients. It is noteworthy that our find-
ings support previous reports that metformin is capable of 
suppressing markers of inflammation such as high-sensitivity 
C-reactive protein in prediabetic individuals42 and TNF-α in 
IR individuals.43 NLR has recently been identified as a predic-
tor of all-cause mortality and cardiovascular events,31 whereas 
previous studies demonstrated a substantial beneficial effect of 
metformin therapy on cardiovascular outcomes.2,44,45 Together, 
these results suggest that suppression of chronic inflammation 
Table 4. Regression Coefficients of Linear Model: Baseline 
NLR>Median
Estimate SE 95% CI P Value
Sex, men 0.1202 0.0427 0.0364 to 0.204 0.0052
Age, y −0.0268 0.0149 −0.0561 to 0.00241 0.0730
Age2, y 0.0002 0.0001 −1.037e−05 to 
0.000444
0.0623
log(NLR) at 
baseline
0.2758 0.0559 0.166 to 0.385 <10–5
Group: 
metformin
−0.1596 0.0551 −0.268 to −0.0517 0.0040
CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.
Table 5. Regression Coefficients of Logistic Model: Baseline 
NLR>Median
Estimate SE 95% CI P Value
Sex, M −0.4841 0.2419 −0.958 to −0.00992 0.0454
Age, y −0.0090 0.0104 −0.0294 to 0.0114 0.3869
log(NLR) at 
baseline
2.2827 0.4423 1.416 to 3.15 <10–5
Group: 
metformin
0.6478 0.3219 0.0168 to 1.279 0.0442
CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.
Table 6. Summary of GoDARTS (Genetics of Diabetes Audit 
and Research in Tayside Scotland) Analyses, Comparing NLR 
in Metformin and Sulfonylurea Groups
Group Analyzed
12-mo Geometric 
Mean NLR Metformin 
vs Sulfonylurea % 
Difference (95% CI)
12-mo NLR<0 mo NLR 
Odds Ratio, Metformin 
vs Sulfonylurea (95% 
CI)
All subjects −9% (2–15) 1.83 (1.22–2.75)
NLR above group 
median
−15% (5–23) 1.91 (1.02–3.59)
CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.
Table 7. ANOVA of Heart Failure Cohort With Treatment 
(Without or With Metformin) as Main Factor With Covariate 
Analysis
Change in 
Cytokine
Covariate
∆BMI ∆BMI and ∆FIRI
Eotaxin/CCL11 F(1,26)=9.881; P=0.004* F(1,26)=9.135; P=0.006*
IL-2 F(1,26)=9.089; P=0.006* F(1,26)=8.078; P=0.009*
IL-4 F(1,26)=8.324; P=0.008* F(1,26)=7.148; P=0.014
MDC/CCL22 F(1,26)=9.887; P=0.004* F(1,26)=9.846; P=0.005*
SDF1αβ/CXCL12 F(1,26)=16.468; P=0.000* F(1,26)=14.661; P=0.001*
BMI indicates body mass index; CCL, C-C motif chemokine ligand; CXCL, 
chemokine (C-X-C motif) ligand; FIRI, Fasting Insulin Resistance Index; IL, 
interleukin; and SDF, stromal cell–derived factor-1.
Significance is taken as *P<0.01 (n=27).
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by metformin might contribute to the difference in outcomes 
between these 2 treatment modalities.
Finally, given the evidence from cells that anti-inflam-
matory and metabolic effects of the drug can be separated, 
we studied a nondiabetic insulin-resistant heart failure cohort 
from a randomized controlled trial. Our research question 
was to determine whether metformin suppressed plasma cy-
tokines. We observed a general trend of metformin treatment 
lowering cytokine concentrations. Correcting for change in 
BMI, 5 cytokines were significantly suppressed by metformin 
but only 2 of these, CCL22 and stromal cell–derived factor 
1αβ, also correlated with change in BMI in follow-up analysis, 
suggesting that in individuals with established CVD, metfor-
min exerts anti-inflammatory effects that are at least in part 
independent of BMI. Four of the 5 cytokines remained sig-
nificant after additional correction for FIRI, and there was 
no significant correlation between change in FIRI and any 
of the cytokines in the panel using a Pearson correlation, 
even though metformin did reduce FIRI. Together these data 
strongly suggest that metformin has effects above and beyond 
the known effects on BMI and insulin sensitivity. The identity 
of these 5 cytokines signpost ways in which anti-inflammatory 
effects of metformin could exert DM-independent therapeutic 
effects in CVD. One earlier cohort study, for example, found 
that a Thr/Ala substitution in the CCL11 gene increases risk 
of myocardial infarction independently of BMI and DM.46 
Blockade of CCL11 can suppress aspects of age-related cel-
lular dysfunction,47 and it is possible that observed effects of 
metformin on mammalian longevity,48,49 where suppression of 
NF-κB is also observed,49 may owe at least in part to suppres-
sion of this cytokine. The other cytokines stromal cell–derived 
factor 1αβ, IL-2, IL-4, and CCL22 are each implicated in reso-
lution of pancreatic β cell inflammation50–53 and stromal cell–
derived factor 1αβ, IL-2, and IL-4 are additionally upregulated 
in plasma from type 2 DM individuals.54,55 Further work will 
be required to determine how the effects on macrophages and 
hepatocytes that we have measured contribute to the changes 
in plasma cytokines observed. Changes in other inflammatory 
cell types, particularly neutrophils given the change in NLR, 
or in cell–cell interactions, may need to be taken into account. 
Altogether our results are consistent with metformin exert-
ing a potentially cardioprotective anti-inflammatory effect in 
patients with CVD, suppressing both age and metabolic in-
flammatory stress markers, independently of effects on BMI, 
insulin sensitivity, and without the onset of frank DM.
We recognize the limitations that are inherent in retrospec-
tive, nonrandomized, observational cohort data. It was impos-
sible to account for all possible confounding influences that 
may have biased the observed differences between the groups 
considered. For example, the BMI of the 2 groups is differ-
ent, consistent with historical prescribing patterns (Tables 7 
and 8). We have sought to minimize these as far as practicable 
by 3 different sensitivity analyses. First, by using a multi-
variate model adjusting for potential confounders; second, by 
performing a propensity score–matched analysis; and third, 
we detected an anti-inflammatory signal in a randomized, 
double-blinded, placebo-controlled trial, providing definitive 
evidence of anti-inflammatory effects of metformin in this 
group of patients. The propensity score–matched analysis 
has been shown to eliminate as much as 90% of treatment 
bias in observational studies.56 Because of the small size of 
the clinical trial, this proof-of-concept study was designed 
and powered only to investigate the study-specific end point 
of peak oxygen uptake in patients with heart failure and not 
on clinical outcome. However, we have previously shown in 
a large population-based cohort study that patients with DM 
and heart failure who were treated with metformin alone or 
in combination with sulfonylureas were at significantly lower 
risk of all-cause mortality during 1 year and long-term follow-
up than those who were treated with sulfonylurea alone.44 Our 
findings on metformin and inflammation will now similarly 
need to be confirmed in other patient cohorts.
In summary, cross-species evidence from cells, plasma, 
patient records, and a randomized placebo-controlled study 
strongly suggest that anti-inflammatory effects should be in-
vestigated further as a potentially important aspect of metfor-
min’s clinical pharmacology that may particularly accelerate 
investigation of their utility in nondiabetic cohorts. There is 
overwhelming evidence that inflammation contributes to the 
development of CVD24 but counterbalancing this is evidence 
from meta-analysis of randomized control trials that existing 
NSAIDs tend to exacerbate risk of CVD.57 If inflammation is 
to be targeted successfully in CVD, new treatment paradigms 
will need to be established. It is likely, for example, that agents 
targeting only selected aspects of inflammation will need to 
be identified. Our work identifying discrete anti-inflammatory 
effects of metformin on cell signaling and plasma parameters 
independently of DM supports ongoing and prospective inves-
tigation into repurposing metformin in a broader spectrum of 
patients with CVD.
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What Is Known?
•	 Observational studies have repeatedly shown benefit of metformin in 
reducing incidence of CVD events in DM.
•	 Inflammation is understood to contribute to CVD cause, but it has been 
difficult to harness anti-inflammatory effects for CVD therapy.
What New Information Does This Article Contribute?
•	 Metformin exhibits an anti-inflammatory action in cells and patients, in 
addition to its known antihyperglycemic effects.
•	 Anti-inflammatory effects of metformin are exerted irrespective of dia-
betes status, providing a nonempirical rationale for further testing of 
the drug in nondiabetic CVD.
Inflammation is understood to contribute to CVD cause, but ex-
isting NSAIDs have shown limited utility in CVD treatment. This 
suggests that other agents, with different anti-inflammatory 
mechanisms, need to be identified for CVD. Observational studies 
have repeatedly shown benefit of metformin in reducing incidence 
of CVD events in diabetes, which do not seem to depend on an-
tihyperglycemic effects alone. In this study, we investigated anti-
inflammatory effects of metformin, as these may contribute to the 
CVD benefit of this drug. We find that this drug acts by inhibiting 
the NF-κB signaling pathway upstream of IKKβ. In further work, 
we find that anti-inflammatory effects of metformin are exerted ir-
respective of diabetes status, including suppression of the ageing-
related cytokine CCL11 in a nondiabetic heart failure cohort. These 
results suggest that metformin suppresses chronic inflammation 
by a different mechanism to NSAIDs and provide a nonempirical 
rationale for further testing of the drug in nondiabetic CVD.
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Supplementary Materials 
Expanded Methods 
I. Animal and Cell Studies 
Metformin and rapamycin came from Calbiochem, AICAR and A769662 (Tocris), 
TNFα (e-bioscience), recombinant CINC1/CXCL1, CCL-11, IL-2, IL-4, SDF and 
CCL22 (R&D systems), mouse IL-6 (Sigma) and recombinant mouse IL-1β (Life 
Technologies). The phospho-acetyl-CoA carboxylase (ACC) Ser79 antibody was a 
generous gift from the DSTT (University of Dundee). The total ACC (Cat. number 
3662), total AMPKα (2603), phospho-AMPKα Thr172 (2535), total S6 (2217), 
phospho-S6 Ser240/244 (2215), total p70 S6 kinase (2708), phospho-p70 S6 kinase 
Thr389 (9205), phospho-Raptor Ser 792 (2083), phospho IKKα/β Ser176/177 
(2078), IKKα/β Ser176/180 (2697), total IκB, pNF-κB, total IKKα and total IKKβ (NF-
κB sampler kit 9936) antibodies were from CST. Anti-sheep HRP (31480) and anti-
rabbit HRP (31460) both came from Thermo and anti-mouse HRP was from 
Calbiochem (JA1200). BI605906 was a generous gift from Prof Sir Philip Cohen. 
Animal Care  
C57BL/6 female mice (Charles River, 8-41 weeks) were maintained under a 12 
hours:12hours light:dark cycle (holding room lights on at 06:00; off at 18:00) at 
22±1◦C and 50% humidity. Mice had ad libitum access to standard chow diet (7.5% 
fat, 75% carbohydrate and 17.5% protein by energy (RM1 diet; Special Diet 
Services) and water. All animal care protocols and procedures were performed in 
accordance with current regulations.  
AMPKα1α2-null (AMPK KO) mice were maintained under a 12-hour light/12-hour 
dark cycle with free access to water and standard mouse diet (in terms of energy: 
65% carbohydrate, 11% fat, 24% protein). These AMPK catalytic subunit deficient 
mice were generated as previously described (1). All procedures were performed in 
accordance with the principles and guidelines established in the European 
Convention for the Protection of Vertebrate Animals Used for Experimental and 
Other Scientific Purposes (Council of Europe, ETS no. 123, 1991).  
 
 
Hepatocyte Extraction 
Mice were killed by cervical dislocation following guidelines set out by the Animals 
(Scientific Procedures) Act 1986. An incision into the abdomen was followed by 
dissection of the skin, abdominal cavity and diaphragm to expose the liver, kidney, 
inferior vena cava and portal vein. The superior vena cava was clamped to isolate 
the hepatic system and the inferior vena cava was cannulated just above the kidney 
with a 25G butterfly needle and clamped in place. Immediately after cannulation, the 
portal vein was cut. Successful cannulation was determined when the liver cleared 
quickly of blood and became pale throughout. The liver was perfused with 50ml pre-
warmed perfusion buffer (137mM NaCl, 7mM KCl, 0.7mM Na2HPO4, 10mM HEPES 
pH 7.65 filter sterilized (0.2 µm) with 0.1% EDTA 0.5M pH 8 added just prior to use) 
at a rate of 5ml/min. After 10 min, the liver was perfused with 50ml digestion buffer 
(perfusion buffer without EDTA with 5.1mM CaCl2 and 20mg collagenase (from 
Clostridium histolyticum type IV, Sigma)); added at a rate of 5ml/min. After digestion, 
the liver was excised from the abdominal cavity and transferred to a cell culture hood 
in a 10cm dish. The liver was resuspended in 10ml of plating media (440ml M199 + 
Glutamax (1x), Invitrogen; 5ml Pen/Strep (100x), Invitrogen; 6.7ml BSA (7.5%), 
Invitrogen; 50ml FBS (foetal bovine serum); 7.7µl Insulin Actrapid (100U/ml), Novo 
Nordisk; 100µl T3 (thyroid hormone 1mM stock), Sigma; 25µl Dexamethasone 
(10mM stock), Merck) and the hepatocytes isolated by gently agitating the liver. Cells 
were filtered through a 100 µm cell strainer and this process was repeated 4 more 
times until a final volume of 50ml was obtained.  Hepatocytes were pelleted by 
centrifugation at 400 rpm for 5 min using no acceleration or braking. The supernatant 
was discarded and the cell pellet resuspended in 25ml plating media by gentle 
inversion. Cell viability was determined by 0.04% Trypan blue staining and the cell 
number determined using a haemocytometer. Cell viability of >90% was required for 
experimental use.  
 
Cell Culture and Lysis for Immunoblotting 
All cells were maintained in an incubator at 37ºC and 5% CO2. For lysate and RT-
PCR experiments, primary mouse hepatocytes were plated in 6-well plates (2.5 x 105 
cells/well in 2ml media) while for glucose assay experiments, primary mouse 
hepatocytes were plated in 12-well plates (1.25 x 105 cells/well in 1ml media). After 4 
hours, plating media was removed, cells were washed with warmed PBS and 
overnight media (500ml M199 + Glutamax (1x); 5ml Pen/Strep (100x); 25µl 
Dexamethasone (10mM stock)) was added at 2ml per well. Cells were incubated 
overnight and experiments were performed the following day. 
BMDMs were grown from mouse bone marrow in RPMI 1640 medium supplemented 
with 10% FBS (Life Technologies) and 10ng/ml M-CSF (R&D systems). Cells were 
given fresh medium and growth factor on day 3 of culture. On day 6, BMDM cultures 
were supplemented with 100ng/ml IFNγ (for M1 differentiation; R&D systems), 
20ng/ml IL-4 (for M2 differentiation; R&D systems), or 100ng/ml LPS (for activation; 
premium grade from Sigma, expected to activate TLR2 and TLR4) in the presence or 
absence of drug treatments for the final 24h. 
Prior to SDS-PAGE, cells were lysed by scraping into buffer A: (50mM Tris acetate 
pH7.5, 1% (w/v) Triton X100, 1mM EDTA, 1mM EGTA, 0.27M sucrose, 50mM NaF, 
1mM sodium orthovanadate, 10mM β-glycerophosphate, 5mM sodium 
pyrophosphate, 1mM benzamidine, 0.2mM phenylmethylsulfonyl fluoride (PMSF) 
and 0.1% (v/v) β-mercaptoethanol) then prepared for SDS-PAGE as follows. The 
lysates were centrifuged at 13 000 g for 15 min, and the supernatants were 
removed. Protein concentration was determined by Bradford assay (Bio-Rad). The 
supernatant was loaded in equal amounts of protein and subjected to 4-20% 
gradient SDS-PAGE and subsequently were transferred to nitrocellulose 
membranes. Primary antibody incubations were performed at dilutions 
recommended by the manufacturer or determined by us in 5% milk TBS-T. All 
incubations were done at 4°C, overnight after a 1 hr block in 5% milk TBS-T. The 
secondary antibody was used at 1:5000 dilution for 1 hr at room temperature. 
Proteins were visualised using the enhanced chemiluminescence (ECL) system 
(Amersham) onto X-ray film (Kodak). Immunoblot densitometry for each antibody 
was performed with Image Studio Lite version 5.2 (LI-COR). Each blot is 
representative of experiments carried out at least three times. 
Glucose Assay 
Treatment of cells for hepatocyte glucose production was performed using primary 
mouse hepatocytes plated in 12-well plates (1.25 x 105 cells/well in 1ml media). 
Glucose production was determined after a 12 hour incubation period in 750µl 
glucose-free DMEM (11966; Life Technologies) supplemented with 1% Pen/Strep, 
lactate (Sigma)/pyruvate (Life Technologies) (10:1 mM) and 100nM dexamethasone 
(dex; Merck) with or without drugs/cytokines under investigation. At the end of the 
incubation period of 12 hours, 500µl of medium was collected and glucose 
concentration determined by GAGO assay (GAGO-20; Sigma) by a modified 
protocol scaled down to a 96-well plate format. 50µl of sample medium followed by 
100µl assay reagent was added to each well with no time delay. Following incubation 
at 37oC for 30 minutes, 100µl 12N H2SO4 was added to each well and mixed using a 
multi-well pipette. Absorbance was measured at 540 nm. Each column consists of 
data from at least 12 wells of cells, six each from two mice. 
RT-PCR 
Primary mouse hepatocytes were incubated for 8 hours in 1ml glucose-free DMEM 
(11966; Life Technologies) supplemented with 1% pen/strep, lactate 
(Sigma)/pyruvate (Life Technologies) (10:1 mM) and 100nM dexamethasone (dex; 
Merck) with or without drugs under investigation. After this incubation period, media 
was removed and cells were washed once with warmed PBS. 350µl of Buffer RLT 
from the Rneasy MINI KIT (Qiagen) plus 10% β-mercaptoethanol was added to each 
well. Plates were then placed on ice for 10 min, followed by a cell harvest and 
samples were snap-frozen immediately in LN2. Total RNA was extracted using 
QIAshredder (Qiagen) and Rneasy MINI KIT (Qiagen) as per the manufacturer’s 
instructions. cDNA was synthesized from 1µg RNA using RQ1 Rnase-Free Dnase kit 
(Promega) and ImProm-II Reverse Transcription System (Promega). cDNA was 
diluted in nuclease-free water 1:10 prior to use.  
Nucleospin RNA II Total RNA isolation kit (Macherey-Nagel) was used to isolate 
RNA from macrophages. cDNA was synthesized from 0.5µg RNA using High 
Capacity cDNA Reverse Transcription Kit (4368814, Thermo Fisher Scientific). 
cDNA was diluted in nuclease-free water 1:2 prior to use. 
Real-time PCR was carried out using the 7900HT Fast Real-Time PCR System 
(Applied Biosystems) using TaqMan 2x Universal PCR Master Mix (Applied 
Biosystems) and primer/probes mixes as stated (Applied Biosystems). Primer sets 
used were: IL-6 Mm00446190_ml; CXCL1 Mm04207460_m1; 18S Hs03003631_g1; 
IL-1β Mm00434228_m1; CXCL2 Mm00436450_m1; PPARγ Mm01184322_m1; 
FASN Mm00662319_m1; CCL22 Mm00436439_ml; CXCL12 Mm00445553_ml; TBP 
Mm01277042_m1 and SREBP-1c Mm00550338_m1. Cycling conditions were: 50°C 
for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. 
Expression is expressed relative to 18s mRNA for hepatocytes and TBP for 
macrophages (Applied Biosystems) using the 2-ΔΔCt method. Control samples were 
set at a value of 100% and results for all experimental samples were graphed as 
relative expression compared to control. Each column is composed of data from at 
least three separate experiments. 
BMDM studies 
BMDMs were harvested from culture plates using 4mM EDTA in PBS for 10min at 
37°C. Cells were washed in flow cytometry buffer (PBS with 2% FBS and 1mM 
EDTA) and stained using the following antibodies (all BD Bioscience unless stated): 
F4/80 (BM8; e-bioscience), CD11c (HL3), CD206 (C068C2; Biolegend), CD69 
(H1.2F3) and CD40 (3/23). Fc block (4.4G2) was included in all stains. Data were 
acquired on a LSR II flow cytometer (Becton Dickinson) and analysed using FlowJo 
software (TreeStar). BMDM culture supernatants were collected after 24 hours 
treatment with the differentiation or activation conditions. Levels of cytokines were 
quantified by standard sandwich ELISA using paired antibody kits (e-bioscience), 
according to the manufacturer’s instructions.  
Statistical Analyses 
Results in bar graphs are expressed as mean ± SEM. Comparisons between groups 
were made by one-way ANOVA with Dunnett’s or Tukey post-hoc test using Prism. 
Differences were considered statistically significant if P was less than 0.05. *** 
denotes p<0.001; ** denotes p<0.01 and * denotes p<0.05. For studies on the 
plasma, statistical analyses of data were performed using SPSS 14.1. ANOVA and 
Pearson correlation coefficients were calculated.  
 
II. Validation in Clinical Patients 
Population Cohort Study: Diabetes Patient Metformin Exposure and 
Neutrophil-to-Lymphocyte Ratio (NLR). 
Sample Ascertainment  
Patients were ascertained from the Diabetes Audit and Research in Tayside 
Scotland (DARTS) study, which has previously been described in detail (2). In brief, 
all the participants were linked through to the Health Informatics Centre Database to 
retrieve validated prescribing information, clinical information system, all 
haematological and biochemistry data and the Scottish Care Information–Diabetes 
Collaboration (SCI-DC) (REF) that provide additional clinical phenotypic data back to 
1992. Prospective longitudinal data were also collected on these patients. The study 
was approved by the Tayside Regional Ethics Committee, and informed consent was 
obtained from all subjects since 1997 to DNA and serum collection as part of the 
Wellcome Trust United Kingdom Type 2 Diabetes Case Control Collection. Over 
17,000 subjects have participated in this Genetics of DARTS (Go-DARTS) study till 
date, of whom over 9,000 have diabetes. 
Hematological Measurements. 
We analysed the electronically linked records of routine laboratory investigations of 
all the participants from the regional biochemistry and hematological database. The 
total and differential leucocyte counts (including the neutrophils and lymphocytes) 
were determined from peripheral venous blood samples using an automated 
Siemens’ high-volume hematology analyzer, the ADVIA® 2120i System (peroxidase 
method) (3). NLR was calculated as the ratio between (percentage of) neutrophils 
and total lymphocyte counts in the study subjects. 
 
Statistical Analysis 
For the population cohort study, characteristics of patients with or without metformin 
therapy were compared by the chi-square test for categorical variables and by the t 
test or Mann-Whitney U test for continuous variables as appropriate. The effect of 
metformin therapy on NLR were examined together with the significant differences 
found at baseline using linear and logistic regression analysis. The following 
covariates were included: age, sex, HbA1c, BMI, duration of followup, prior 
hospitalisation for COPD, Atrial Fibrilation or Hypertension, and baseline NLR. To 
minimize confounding influences, we performed two different sensitivity analysis. 
First, by using a multivariate model adjusting for potential confounders; second we 
determined a propensity score using a logistic regression model to control for the 
different characteristics of the metformin and sulfonylurea groups. A P-value of <0.05 
was considered significant and all statistical analysis for this cohort study were 
performed using R for windows (v3.2.0).   
Randomised Placebo Controlled Study 
The effect of metformin on plasma inflammatory cytokines were further investigated 
in a subset of chronic heart failure (CHF) patients who had participated in a double-
blind, placebo-controlled study of metformin, which has previously been described in 
detail (4). In brief, this study was designed and powered to evaluate the impact of 
metformin on IR and its effects on exercise capacity in non-diabetic IR patients with 
CHF. Every patient who participated in this study, provided written informed consent 
prior to participation in this study, which was approved by the East of Scotland 
Research Ethics Service (www.clinicaltrials.gov: NCT00473876). In this study we 
had shown that metformin treatment significantly improved IR but had no significant 
effect on the primary endpoint of exercise capacity, as measured by peak VO2. 
However, metformin treatment did result in a significant improvement in the minute 
ventilation − carbon dioxide production relationship (VE/VCO2 slope), a pre-specified 
secondary endpoint of this proof of concept study which is of prognostic significance 
in patients with CHF, and in some studies, it has outperformed peak VO2 (5). 
Cytokine Assay  
We analysed plasma from 33 non-diabetic insulin resistant heart failure patients who 
took part in a placebo controlled clinical trial of metformin (4). The plasma was 
analysed using the Bio-Plex Pro Human Chemokine 40-Plex Panel (171-AK99MR2, 
Bio-Rad). The assay was performed following the manufacturer’s instructions using 
the Bio-Plex 200 system (Bio-Rad). Freeze-thaw cycling of samples was avoided to 
prevent cytokine degradation and they were diluted 1:4 (12.5µl of plasma) for the 
assay. 
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Supplementary table I. Cytokine measurements 
  Baseline 
  Placebo (n=13) Metformin (n=20) 
Cytokine (pg/ml) Average SD Average SD 
CCL21/6Ckine 5454.29 2067.61 5890.92 1853.73
BCA-1/CXCL13 28.52 9.54 35.02 13.22 
CTACK/CCL27 1723.32 583.41 1973.63 815.37 
ENA-78/CXCL5 642.91 213 781.07 321.26 
Eotaxin/CCL11 51.4 13.67 60.8 17.69 
Eotaxin-2/CCL24 685.11 518.81 640.79 402.68 
Eotaxin-3/CCL26 56.27 18.48 74.93 60.97 
Fractalkine/CX3CL1 172.05 61.95 237.93 93.3 
GCP-2/CXCL6 20.34 8.37 26.27 14.34 
GM-CSF 128.91 50.39 137.67 52.51 
Gro-α/CXCL1 348.61 83.78 336.15 76.27 
Gro-β/CXCL2 153.61 74.54 235.74 178.19 
I-309/CCL1 83.83 17.2 92.43 18.49 
IFNγ 64.35 20.88 75.98 27.42 
IL-1β 7.53 3.66 9.33 3.84 
IL-2 15.96 5.21 18.87 6.48 
IL-4 32.19 7.45 33.4 9.48 
IL-6 14.14 3.89 17.81 8.58 
IL-8/CXCL8 14.19 4.16 16.9 4.72 
IL-10 46.74 21.99 54.49 22.46 
IL-16 329.73 120.54 364.8 130.41 
IP-10/CXCL10 173.62 67.61 206.57 114.88 
I-TAC/CXCL11 18.02 6.86 23.33 7.83 
MCP-1/CCL2 69.92 33.76 86.03 52.74 
MCP-2/CCL8 56.84 21.19 70.44 38.9 
MCP-3/CCL7 126.6 35.08 146.64 53.26 
MCP-4/CCL13 77.59 46.32 69.26 39.3 
MDC/CCL22 1014.65 290 1151.86 505.54 
MIF 6303.03 5822.99 5681.16 3323.86
MIG/CXCL9 296.66 136.95 404.71 277.22 
MIP-1α/CCL3 10.5 2.02 12.22 3.69 
MIP-1δ/CCL15 7487.28 3978.97 7716.92 4125.49
MIP-3α/CCL20 34.9 79.52 37.84 43.88 
MIP-3β/CCL19 353.04 252.2 463.93 308.82 
MPIF-1/CCL23 446.78 221.81 494.74 211.13 
SCYB16/CXCL16 503.06 216.96 567.01 228.79 
SDF-1α+β/CXCL12 1257.91 423.96 1487.04 500.84 
TARC/CCL17 113.29 81.29 138.35 94.4 
TECK/CCL25 759.25 248.21 896.76 327.17 
TNFα 46.33 10.03 51.18 15.66 
  Change after 4 months metformin treatment     
  Placebo (n=13) Metformin (n=20) BMI (p 
value) 
BMI & 
FIRI (p 
value) Cytokine (pg/ml) Average SD Average SD 
CCL21/6Ckine 99.20 756.47 55.16 2595.81 0.857 0.8 
BCA-1/CXCL13 3.92 7.29 2.34 14.28 0.036 0.029 
CTACK/CCL27 54.09 401.40 -128.67 902.78 0.022 0.032 
ENA-78/CXCL5 29.79 148.93 -60.30 375.81 0.02 0.025 
Eotaxin/CCL11 5.18 8.94 -0.36 17.00 0.004 * 0.006 * 
Eotaxin-2/CCL24 32.73 258.03 -21.23 210.01 0.309 0.356 
Eotaxin-3/CCL26 6.54 13.67 -11.50 54.48 0.038 0.053 
Fractalkine/CX3CL1 0.93 56.10 -25.89 107.44 0.085 0.081 
GCP-2/CXCL6 0.91 6.29 1.05 13.11 0.169 0.216 
GM-CSF 1.52 34.36 3.15 55.77 0.051 0.05 
Gro-α/CXCL1 11.01 54.90 5.89 80.00 0.101 0.106 
Gro-β/CXCL2 32.80 56.92 9.41 120.75 0.317 0.365 
I-309/CCL1 6.16 10.89 -0.69 17.79 0.011 0.014 
IFNγ 6.28 16.04 -1.85 29.38 0.019 0.025 
IL-1β 0.16 2.90 -0.96 4.15 0.116 0.098 
IL-2 1.47 3.17 -0.95 6.96 0.006 * 0.009 * 
IL-4 1.33 4.55 -2.67 11.90 0.008 * 0.014 
IL-6 0.86 3.43 2.75 14.94 0.022 0.027 
IL-8/CXCL8 1.87 3.94 0.20 8.25 0.07 0.072 
IL-10 6.79 14.29 -4.43 27.19 0.019 0.024 
IL-16 32.62 82.96 -19.07 149.55 0.013 0.021 
IP-10/CXCL10 -3.82 52.93 16.13 118.54 0.958 0.893 
I-TAC/CXCL11 2.22 7.06 3.73 13.73 0.989 0.955 
MCP-1/CCL2 12.78 26.27 -5.34 35.48 0.039 0.055 
MCP-2/CCL8 9.01 16.58 -2.92 38.04 0.048 0.071 
MCP-3/CCL7 13.07 31.37 -7.03 55.42 0.025 0.029 
MCP-4/CCL13 -3.31 25.83 3.02 37.95 0.377 0.418 
MDC/CCL22 93.18 244.23 -47.75 453.81 0.004 * 0.005 * 
MIF -1711.46 5475.63 -829.75 3572.37 0.436 0.464 
MIG/CXCL9 52.40 128.26 -3.84 200.65 0.016 0.019 
MIP-1α/CCL3 0.72 1.66 -0.52 2.67 0.013 0.013 
MIP-1δ/CCL15 -300.03 2502.48 515.34 4045.71 0.505 0.368 
MIP-3α/CCL20 -16.84 61.17 -4.44 45.65 0.832 0.991 
MIP-3β/CCL19 97.36 212.33 -77.06 343.62 0.018 0.024 
MPIF-1/CCL23 -16.10 95.08 -29.21 177.39 0.26 0.214 
SCYB16/CXCL16 -11.35 114.84 30.26 203.08 0.083 0.11 
SDF-1α+β/CXCL12 103.67 198.81 -49.25 409.72 0 * 0.001 * 
TARC/CCL17 29.45 72.26 -20.89 96.02 0.022 0.03 
  
Supplementary table II. Metabolic, haemodynamic and other characteristics of patients 
  Baseline   
  Placebo (n=13) Metformin (n=20) p value 
Sex 
Male  12; Female 
1 Male 16; Female 4   
  Average SD Average SD   
Age 64.23 6.99 62.70 7.04 0.408 
Metabolism 
Parameters           
Body Mass Index 29.37 5.11 30.19 5.23 0.319 
Insulin (mU/L) 22.63 11.54 27.47 15.29 0.144 
Glucose (mmol/L) 5.37 0.42 5.61 0.66 0.331 
Fasting Insulin 
Resistance Index (log) 4.90 2.57 6.32 3.92 0.134 
Severity of Heart 
Failure           
Brain Natriuretic Peptide 
(pg/ml) 116.27 131.98 139.09 197.95 0.750 
Ejection Fraction (%) 28.82 8.29 37.29 7.93 0.016 
Haemodynamic 
Conditions          
Resting Systolic Blood 
Pressure (mmHg) 116.54 21.05 107.60 9.68 0.101 
Resting Diastolic Blood 
Pressure (mmHg) 75.15 10.38 69.35 7.15 0.178 
Resting Heart Rate 70.08 21.22 68.60 14.44 0.992 
Peak VO2 (mL/kg/min) 18.02 5.94 19.72 4.75 0.776 
VE/VCO2 slope 30.65 5.31 31.64 6.03 0.244 
Total exercise duration 
(s)  954.15 355.64 1063.80 204.51 0.469 
 
 
 
 
 
 
TECK/CCL25 54.31 180.75 -57.17 354.85 0.019 0.026 
TNFα 4.91 8.98 0.09 18.93 0.03 0.036 
Significance taken as * p < 0.01.  
 
 
 
  
Change after 4 months metformin 
treatment   
  Placebo (n=13) 
Metformin 
(n=20) p value 
  Average SD Average SD   
Metabolism 
Parameters           
Body Mass Index 0.46 0.76 -1.16 1.08 0.000 
Insulin (mU/L) 0.92 7.39 -6.39 9.19 0.044 
Glucose (mmol/L) -0.02 0.75 -0.29 0.50 0.042 
Fasting Insulin 
Resistance Index (log) 0.26 1.77 -1.81 2.53 0.029 
Severity of Heart 
Failure           
Brain Natriuretic Peptide 
(pg/ml) 17.26 122.33 -22.24 91.36 0.383 
Ejection Fraction (%) -0.89 2.52 -1.03 3.61 0.681 
Haemodynamic 
Conditions           
Resting Systolic Blood 
Pressure (mmHg) -7.15 16.18 0.80 14.63 0.049 
Resting Diastolic Blood 
Pressure (mmHg) -4.69 9.22 -0.45 7.84 0.177 
Resting Heart Rate 1.00 11.73 2.70 9.95 0.451 
Peak VO2 (mL/kg/min) 1.25 4.59 -0.91 2.73 0.334 
VE/VCO2 slope 1.86 10.57 -4.52 5.37 0.029 
Total exercise duration 
(s)  7.08 92.03 -22.75 99.45 0.671 
 
Supplementary figure legends 
Supplementary Figure I. Densitometry of blots in main figure 1 
Densitometry was carried out as described in the methods to quantify data obtained 
in western blots. Bars significantly different from the respective control treatment (+/- 
TNFα) are shown, ***p<0.001, **p<0.01, *p<0.05. N=3 except for IκBa and pACC, 
N=4 
Supplementary Figure II. Densitometry of blots in main figure 2 
Densitometry was carried out as described in the methods to quantify data obtained 
in western blots. In experiments comparing wild-type (WT) and knockout (KO) 
genotype, black bars denote WT genotype, grey bars denote KO genotype. Bars 
significantly different from the respective control treatment (+/- TNFα) are shown, 
***p<0.001, **p<0.01, *p<0.05, except in knockout experiments, where significance 
between genotypes is depicted. N=3 
Supplementary Figure III. Effect of metformin on gene expression in 
macrophages: genes regulated in hepatocytes 
Macrophages were treated with or without 100ng/ml LPS +/- 2mM metformin for 8h 
followed by cell lysis, RNA extraction and preparation of cDNA for RTPCR using 
primer sets for individual genes shown, as described in the methods. Bars 
significantly different from control treatment, or between two annotated bars are 
shown, ***p<0.001, *p<0.05 
 
Supplementary Figure IV. Effect of metformin on gene expression in 
macrophages and hepatocytes: genes changed by metformin in human 
plasma 
Macrophages (a,b) were treated with/without 100ng/ml LPS +/- 2mM metformin, 
while hepatocytes (c) were treated with/without 10ng/ml TNFα +/- 2mM metformin or 
10mM BI605906 as shown, for 8h followed by cell lysis, RNA extraction and 
preparation of cDNA for RTPCR using primer sets for individual genes shown, as 
described in the methods. Bars significantly different from control treatment, or 
between two annotated bars are shown, ***p<0.001, **p<0.01, *p<0.05 
 
Supplementary Figure V. Densitometry of blots in main figure 5 
Densitometry was carried out as described in the methods to quantify data obtained 
in western blots. In experiments comparing wild-type (WT) and knockout (KO) 
genotype, black bars denote WT genotype, grey bars denote KO genotype. Bars 
significantly different from the respective control treatment (+/- TNFα) are shown, 
***p<0.001, **p<0.01, *p<0.05, except in knockout experiments, where significance 
between genotypes is depicted. N=3 
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